FDA — authorised 18 July 1974
- Application: ANDA083320
- Marketing authorisation holder: ALRA
- Local brand name: ACETAZOLAMIDE
- Indication: TABLET — ORAL
- Status: approved
🇺🇸 best medical care in United States
FDA authorised best medical care on 18 July 1974
Marketing authorisations
FDA — authorised 31 March 1978
- Application: ANDA084840
- Marketing authorisation holder: CHARTWELL MOLECULAR
- Local brand name: ACETAZOLAMIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 5 February 1982
- Application: ANDA087654
- Marketing authorisation holder: VANGARD
- Local brand name: ACETAZOLAMIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 22 October 1985
- Application: ANDA088882
- Marketing authorisation holder: HERITAGE PHARMA
- Local brand name: ACETAZOLAMIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 22 June 1988
- Application: ANDA089753
- Marketing authorisation holder: SUN PHARM INDUSTRIES
- Local brand name: ACETAZOLAMIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 10 December 2008
- Application: ANDA040904
- Marketing authorisation holder: HERITAGE PHARMA
- Local brand name: ACETAZOLAMIDE
- Indication: CAPSULE, EXTENDED RELEASE — ORAL
- Status: approved
FDA — authorised 14 July 2011
- Application: ANDA090779
- Marketing authorisation holder: INDICUS PHARMA
- Local brand name: ACETAZOLAMIDE
- Indication: CAPSULE, EXTENDED RELEASE — ORAL
- Status: approved
FDA — authorised 29 March 2016
- Application: ANDA204691
- Marketing authorisation holder: MPP PHARMA
- Local brand name: ACETAZOLAMIDE
- Indication: CAPSULE, EXTENDED RELEASE — ORAL
- Status: approved
FDA — authorised 30 September 2016
- Application: ANDA203434
- Marketing authorisation holder: NOVAST LABS
- Local brand name: ACETAZOLAMIDE
- Indication: CAPSULE, EXTENDED RELEASE — ORAL
- Status: approved
FDA — authorised 27 October 2016
- Application: ANDA205530
- Marketing authorisation holder: HERITAGE PHARMA
- Local brand name: ACETAZOLAMIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 20 November 2017
- Application: ANDA209734
- Marketing authorisation holder: STRIDES PHARMA
- Local brand name: ACETAZOLAMIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 18 October 2018
- Application: ANDA207659
- Marketing authorisation holder: ACCORD HLTHCARE
- Local brand name: ACETAZOLAMIDE
- Indication: CAPSULE, EXTENDED RELEASE — ORAL
- Status: approved
FDA — authorised 16 January 2019
- Application: ANDA205301
- Marketing authorisation holder: CADILA
- Local brand name: ACETAZOLAMIDE
- Indication: CAPSULE, EXTENDED RELEASE — ORAL
- Status: approved
FDA — authorised 19 February 2019
- Application: ANDA210423
- Marketing authorisation holder: ALEMBIC
- Local brand name: ACETAZOLAMIDE
- Indication: CAPSULE, EXTENDED RELEASE — ORAL
- Status: approved
FDA — authorised 18 June 2019
- Application: ANDA203917
- Marketing authorisation holder: RISING
- Local brand name: ACETAZOLAMIDE
- Indication: CAPSULE, EXTENDED RELEASE — ORAL
- Status: approved
FDA — authorised 17 October 2019
- Application: ANDA210588
- Marketing authorisation holder: NOVITIUM PHARMA
- Local brand name: ACETAZOLAMIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 18 October 2019
- Application: ANDA211556
- Marketing authorisation holder: HIBROW HLTHCARE
- Local brand name: ACETAZOLAMIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 30 April 2020
- Application: ANDA207503
- Marketing authorisation holder: BRECKENRIDGE
- Local brand name: ACETAZOLAMIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 22 February 2021
- Application: ANDA211372
- Marketing authorisation holder: SOMERSET THERAPS LLC
- Local brand name: ACETAZOLAMIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 19 August 2021
- Application: ANDA215101
- Marketing authorisation holder: RUBICON RESEARCH
- Local brand name: ACETAZOLAMIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 4 April 2023
- Application: ANDA211069
- Marketing authorisation holder: ZYDUS LIFESCIENCES
- Local brand name: ACETAZOLAMIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 9 May 2023
- Application: ANDA217197
- Marketing authorisation holder: NE RX PHARMA
- Local brand name: ACETAZOLAMIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 11 September 2023
- Application: ANDA211151
- Marketing authorisation holder: AJANTA PHARMA LTD
- Local brand name: ACETAZOLAMIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 26 January 2024
- Application: ANDA213706
- Marketing authorisation holder: TORRENT
- Local brand name: ACETAZOLAMIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 14 May 2024
- Application: ANDA218023
- Marketing authorisation holder: EPIC PHARMA LLC
- Local brand name: ACETAZOLAMIDE
- Indication: TABLET — ORAL
- Status: approved
FDA — authorised 30 May 2025
- Application: ANDA212089
- Marketing authorisation holder: AUROBINDO PHARMA LTD
- Local brand name: ACETAZOLAMIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA087686
- Marketing authorisation holder: ASCOT
- Local brand name: ACETAZOLAMIDE
- Indication: TABLET — ORAL
- Status: approved
FDA
- Application: ANDA084498
- Marketing authorisation holder: WATSON LABS
- Local brand name: ACETAZOLAMIDE
- Indication: TABLET — ORAL
- Status: approved
Frequently asked questions
Is best medical care approved in United States?
Yes. FDA authorised it on 18 July 1974; FDA authorised it on 31 March 1978; FDA authorised it on 5 February 1982.
Who is the marketing authorisation holder for best medical care in United States?
ALRA holds the US marketing authorisation.